- Home
- PLX vs MAPS Comparison
PLX vs MAPS Comparison
Compare PLX & MAPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- MAPS
- Stock Information
- Founded
- PLX 1993
- MAPS 2008
- Country
- PLX United States
- MAPS United States
- Employees
- PLX N/A
- MAPS N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- MAPS Computer Software: Prepackaged Software
- Sector
- PLX Health Care
- MAPS Technology
- Exchange
- PLX Nasdaq
- MAPS Nasdaq
- Market Cap
- PLX 160.2M
- MAPS 131.9M
- IPO Year
- PLX 1998
- MAPS N/A
- Fundamental
- Price
- PLX $2.87
- MAPS $1.17
- Analyst Decision
- PLX Strong Buy
- MAPS Strong Buy
- Analyst Count
- PLX 1
- MAPS 1
- Target Price
- PLX $15.00
- MAPS $2.61
- AVG Volume (30 Days)
- PLX 753.1K
- MAPS 612.1K
- Earning Date
- PLX 05-09-2025
- MAPS 05-08-2025
- Dividend Yield
- PLX N/A
- MAPS N/A
- EPS Growth
- PLX N/A
- MAPS N/A
- EPS
- PLX 0.04
- MAPS 0.08
- Revenue
- PLX $53,399,000.00
- MAPS $184,514,000.00
- Revenue This Year
- PLX $65.02
- MAPS $0.86
- Revenue Next Year
- PLX $57.34
- MAPS $12.85
- P/E Ratio
- PLX $79.67
- MAPS $14.24
- Revenue Growth
- PLX N/A
- MAPS N/A
- 52 Week Low
- PLX $0.82
- MAPS $0.70
- 52 Week High
- PLX $3.10
- MAPS $1.65
- Technical
- Relative Strength Index (RSI)
- PLX 56.85
- MAPS 50.93
- Support Level
- PLX $2.70
- MAPS $1.11
- Resistance Level
- PLX $2.64
- MAPS $1.31
- Average True Range (ATR)
- PLX 0.17
- MAPS 0.06
- MACD
- PLX -0.01
- MAPS 0.01
- Stochastic Oscillator
- PLX 61.67
- MAPS 51.72
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About MAPS WM Technology Inc.
WM Technology Inc is a technology and software infrastructure provider to the cannabis industry. It comprises B2C platform Weedmaps, and B2B software WM Business. Its revenues are derived primarily from monthly subscriptions to Weedmaps for Business, featured and deal listings and other WM Ad solutions. The Weedmaps for Business subscriptions generally have one-month terms that automatically renew unless notice of cancellation is provided in advance. Featured and deal listings and other WM Ad solutions are offered as add-on products to the Weedmaps for Business subscriptions. Featured and deal listings provide customers with premium placement ad solutions and discount and promotion pricing tools. Other WM Ad solutions include banner ads and promotion tiles on our marketplace ads.